Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211363 · ClinicalTrials.gov registry record · Phase 3
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
A Phase 3 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 439
- Enrollment target
NCT04211363 is a Phase 3 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 439 participants.
The verdict
NCT04211363, a Phase 3 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 439 participants
- Enrollment target
Study Summary
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.
Interventions
- DRUG Vehicle Cream
- DRUG Roflumilast 0.3% cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2020-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04211363
The ClinicalTrials.gov registry entry for NCT04211363 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Cream is the first listed.
NCT04211363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04211363 about?
NCT04211363 is a clinical study titled "Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis". This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.
What is the current status of trial NCT04211363?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2019-12-20. Estimated completion is 2020-11-16.
What interventions are being tested in trial NCT04211363?
The interventions under investigation include: Vehicle Cream (DRUG), Roflumilast 0.3% cream (DRUG).
Who is sponsoring clinical trial NCT04211363?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.